CN104270944A - 用于癌症的葡磷酰胺组合疗法 - Google Patents

用于癌症的葡磷酰胺组合疗法 Download PDF

Info

Publication number
CN104270944A
CN104270944A CN201280072538.2A CN201280072538A CN104270944A CN 104270944 A CN104270944 A CN 104270944A CN 201280072538 A CN201280072538 A CN 201280072538A CN 104270944 A CN104270944 A CN 104270944A
Authority
CN
China
Prior art keywords
cancer
glufosfamide
glucose
clean
gelie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280072538.2A
Other languages
English (en)
Chinese (zh)
Inventor
埃德温·J·托马斯
马修·帕里斯
福利斯特·H·安东尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eleison Pharmaceuticals LLC
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of CN104270944A publication Critical patent/CN104270944A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280072538.2A 2012-04-19 2012-08-31 用于癌症的葡磷酰胺组合疗法 Pending CN104270944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261687114P 2012-04-19 2012-04-19
US61/687,114 2012-04-19
PCT/US2012/053275 WO2013158143A1 (en) 2012-04-19 2012-08-31 Glufosfamide combination therapies for cancer

Publications (1)

Publication Number Publication Date
CN104270944A true CN104270944A (zh) 2015-01-07

Family

ID=49380659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280072538.2A Pending CN104270944A (zh) 2012-04-19 2012-08-31 用于癌症的葡磷酰胺组合疗法

Country Status (7)

Country Link
US (1) US20130281386A1 (enExample)
EP (1) EP2846638A4 (enExample)
JP (3) JP2015514756A (enExample)
CN (1) CN104270944A (enExample)
CA (1) CA2870138A1 (enExample)
HK (1) HK1207796A1 (enExample)
WO (1) WO2013158143A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030798A (zh) * 2015-06-24 2015-11-11 李宏 一种抗肿瘤的药物组合物及其制备方法和应用
CN110248664A (zh) * 2017-11-28 2019-09-17 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134486A1 (en) * 2015-02-27 2016-09-01 Steinberg Gregory Use of canagliflozin and derivatives thereof in the treatment of cancer
US20210283100A1 (en) * 2016-08-01 2021-09-16 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
EP3927378A1 (en) * 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
CN110038009B (zh) 2019-05-13 2021-01-08 浙江大学 卡格列净在制备抗肿瘤药物中的应用
KR102437311B1 (ko) * 2019-12-03 2022-09-15 주식회사 하임네이처 Ndpk 활성제 및 sglt-2 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20210084919A (ko) * 2019-12-30 2021-07-08 주식회사 하임바이오 Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
EP4203941A4 (en) * 2020-08-26 2025-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. COMBINATION THERAPY TO REDUCE DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
AU2003230750A1 (en) * 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
JP2006521562A (ja) * 2003-03-07 2006-09-21 スレショルド ファーマシューティカルズ インコーポレイティッド 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法
JP2008540559A (ja) * 2005-05-11 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド グルフォスファミド併用療法
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
US20100104549A1 (en) * 2007-04-05 2010-04-29 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASFANDYAR KHAN NIAZI, SAAD HAMEED NIAZI: "A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors", 《NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES》, vol. 2, no. 12, 31 December 2010 (2010-12-31), pages 557 - 559, XP055171194 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030798A (zh) * 2015-06-24 2015-11-11 李宏 一种抗肿瘤的药物组合物及其制备方法和应用
CN110248664A (zh) * 2017-11-28 2019-09-17 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途
CN110248664B (zh) * 2017-11-28 2023-03-03 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途

Also Published As

Publication number Publication date
EP2846638A1 (en) 2015-03-18
JP2015514756A (ja) 2015-05-21
US20130281386A1 (en) 2013-10-24
EP2846638A4 (en) 2016-03-02
CA2870138A1 (en) 2013-10-24
WO2013158143A1 (en) 2013-10-24
JP2020055884A (ja) 2020-04-09
JP2018087228A (ja) 2018-06-07
HK1207796A1 (en) 2016-02-12

Similar Documents

Publication Publication Date Title
CN104270944A (zh) 用于癌症的葡磷酰胺组合疗法
US20230404999A1 (en) Combination therapy with an antitumor alkaloid
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
ES2661216T3 (es) Método combinado para tratar el cáncer o un estado precanceroso
EP2817011B1 (en) Treatment of cancer
JP2016501884A5 (enExample)
EP4087572A1 (en) Combination therapy for treating cancer
US8765690B2 (en) Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2012131487A2 (en) Compositions and methods for the treatment of cancer
US20240390352A1 (en) Pharmaceutical composition for preventing or treating cancer comprising carnitine acylcarnitine carrier inhibitor and antitumor agent
JP2006527753A (ja) 結腸直腸癌などの治療のための、血管損傷効果を有する、５−ｆｕ、ｃｐｔ−１１または５−ｆｕおよびｃｐｔ−１１と組み合わせたｚｄ６１２６を含んでなる組成物
Korsch Investigation of Alternative Treatment Options for Pancreatic Cancer
AU2009316773A1 (en) Anticancer combination comprising docetaxel and an antisense oligonucleotide
OA21163A (en) Combination of a BCL-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof.
JP2018104291A (ja) マグネシウム化合物を有効成分として含有することを特徴とする医薬組成物
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
Franceschini et al. WJBC
Hariprasad et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1204956B (en) Treatment of cancer
JP2018104292A (ja) マグネシウム化合物を有効成分とする医薬組成物
HK1188572B (en) Combination therapy with an antitumor alkaloid
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2004032939A1 (en) Combination therapy with gemcitabine and zd6126

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150107

WD01 Invention patent application deemed withdrawn after publication